Compare DexCom, Inc. (DXCM) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Ultra Short Bond ETF — how do they compare? DexCom, Inc. trades at $89.2 (market cap $33.79B), while Vanguard Ultra Short Bond ETF trades at $49.67. The key difference: DexCom, Inc. is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | VUSB | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $89.53 | $50.03 |
52-Week Low | $54.84 | $49.60 |
Enterprise Value | $33.24B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
